Deciphera Pharmaceuticals to Present Data on its Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, at American Association for Cancer Research Annual Meeting 2016

Presentation of Preclinical Data on Efficacy of DCC-3014, a potent macrophage checkpoint inhibitor, as both single agent and in combination with an anti-PD1 inhibitor Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that an abstract highlighting the company’s highly-selective small molecule CSF1R inhibitor, DCC-3014, has been selected for presentation at the American Association for Cancer Research Annual Meeting 2016, taking place April 16-20, 2016 in New Orleans. DCC-3014 was designed as a highly-specific macrophage immunomodulatory agent based on the company’s Switch Control Inhibitor platform. In preclinical cancer models, DCC-3014 was shown to significantly enhance anti-tumor activity when used in combination with an anti-PD-1 checkpoint inhibitor. Deciphera expects to initiate a Phase 1 clinical trial of DCC-3014 in the second half of 2016. “We are pleased to present data at the AACR Annual Meeting 2016 demonstrating DCC-3014’s robust inhibition of the CSF1R kinase, both as a single agent and in combination with an anti-PD1 inhibitor, across a number of cancer models,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. “We look forward to initiating the first-in-human Phase 1 trial with DCC-3014 later this year.” Details of the Poster Presentations on DCC-3014: Poster Title: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models Author: Smith, Bryan D. Abstract #: 4889 Session: Immune Modulating Agents 2 Date & Time: Wednesday, April 20, 2016, 8:00 AM – 12:00 PM Location: Halls G-J, Poster Section 2. Poster Board #30 Contacts: Michael D. Taylor, Ph.D., Deciphera Pharmaceuticals [email protected] 781-209-6411 Media: Gina Nugent, The Yates Network [email protected] 617-460-3579 twitter linkedin contact us Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3009 Inlexisertib DCC-2812 Expanded Access Our Medicine About Management Join Us Open Positions Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement Compliance Hotline Consent Manager © 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo. Back to top

The release as fetched from its publisher. deciphera.com ↗